Rational Pharmacotherapy in Cardiology

Advanced search

Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy

Full Text:


The association of non-alcoholic fatty liver disease (NAFLD) and cardiovascular risk is currently one of the actively studied areas. The incidence of non-alcoholic fatty  liver disease continues to grow worldwide. In the structure of mortality rate of patients with non-alcoholic fatty  liver disease,  the first place is occupied by cardiovascular events: stroke and myocardial infarction. Studies have shown that the presence of severe liver fibrosis (F3-4) in NAFLD not only increases the risk of cardiovascular diseases (CVD), but also increases the risk  of  overall  mortality  by  69%  due  to mortality from cardiovascular causes. The degree of increased risk is associated with the degree of activity of non-alcoholic steatohepatitis (NASH). Despite the large number of works on this topic, we do not have a clear opinion on the impact on cardiovascular risk, interaction and the contribution of various factors, as well as algorithms for managing patients with non-alcoholic fatty liver disease to reduce the risk of cardiovascular diseases. This article describes the pathogenetic factors of formation of cardiovascular risks in patients with non-alcoholic fatty liver disease, proposed the idea of stratification of cardiovascular risks in these patients, taking into account changes in the structure of the liver (fibrosis) and function (clinical and biochemical activity) and also it describes the main directions of drug therapy, taking into account the common pathogenetic mechanisms for non-alcoholic fatty liver disease and cardiovascular diseases. The role of obesity, local fat depots, adipokines, and endothelial dysfunction as the leading pathogenetic factors of increased cardiovascular risk in patients with NAFLD is discussed. Among pathogenetically justified drugs in conditions of poly and comorbidity, hypolipidemic (statins, fibrates), angiotensin II receptor antagonists, beta-blockers, etc. can be considered. According to numerous studies, it becomes obvious that the assessment of cardiovascular risks in patients with NAFLD will probably allow prescribing cardiological drugs, selecting individualized therapy regimens, taking into account the form of NAFLD, and on the other hand, building curation taking into account the identified cardiovascular risks.

About the Authors

A. V. Nelidova
Omsk State Medical University
Russian Federation

Anastasiya V. Nelidova.


eLibrary SPIN 1506-3007

M. A. Livzan
Omsk State Medical University
Russian Federation

Maria A. Livzan.


eLibrary SPIN 1961-4082

N. A. Nikolaev
Omsk State Medical University
Russian Federation

Nikolay A. Nikolaev.


eLibrary  SPIN  8807-9519

T. S. Krolevets
Omsk State Medical University
Russian Federation

Tatyana S. Krolevets.


eLibrary    SPIN    8043-5634


1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. DOI:10.1016/j.jhep.2015.11.004.

2. Ivashkin VT, Mayevskaya MV, Pavlov CS, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24-42 (In Russ.) DOI:10.22416/1382-4376-2016-26-2-24-42.

3. Lazebnik LB, Radchenko VG, Golovanova ЕV, et al. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (recommendations for therapists, 2nd edition). Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017;138(2):22-37 (In Russ.)

4. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):7384. DOI:10.1002/hep.28431.

5. Maev IV, Kuznetsova EI, Andreev DN, Dicheva DT. Current and future approaches to the diagnosis of non-alcoholic fatty liver disease. Consilium Medicum. 2015;17(8):20-7 (In Russ.)

6. Abd El-Kader S.M, El-Den Ashmawy E.M. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol. 2015;7(6):846-858. DOI:10.4254/wjh.v7.i6.846.

7. Balukova EV. Non-alcoholic fatty liver disease and the risk of cardiovascular events. Russian Medical Journal. 2013;21(13):737-40 (In Russ.)

8. Drapkina OM, Smirin VI, Ivashkin VT. Non-alcoholic fatty liver disease - a modern view of the problem. Lechashiy Vrach. 2010;5:57-61 (In Russ.)

9. Akhmedov VA, Gaus OV. Current Non-Invasive Methods for Diagnosing Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Doctor.Ru. 2017;2(131):11-4 (In Russ.)

10. Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589-600. DOI:10.1016/j.jhep.2016.05.01.

11. Drapkina OM, Yafarova AA. Non-alcoholic fatty liver disease and cardiovascular risk: scientific problem state. Rational Pharmacotherapy in Cardiology. 2017;13(5):645-650. (In Russ.) DOI:10.20996/1819-6446-2017-13-5-645-65014.

12. Drapkina OM, Korneeva ON. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016;12(4):424-9 (In Russ.) DOI:10.20996/1819-6446-2016-12-4-424-429.

13. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646-50. DOI:10.1016/j.cgh.2011.12.039.

14. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6);330-44. DOI:10.1038/nrgastro.2013.41.

15. Shirokova EN. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. 2017;8(2):74-6 (In Russ.) DOI:10.26442/2075-1753_19.8.2.74-76.

16. Drapkina OM, Korneeva ON. Metabolic syndrome and cardiovascular diseases in women. How big is the influence of gender? Serdce. 2011;10(4):224-8 (In Russ.)

17. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357-65. DOI:10.1002/hep.26156.

18. Treeprasertsuk S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012;32:945-50. DOI:10.1111/j.1478-3231.2011.02753.x.

19. Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011;60:1721-7. DOI:10.1136/gut.2011.242016.

20. Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017;8(2):51-8. DOI:10.4291/wjgp.v8.i2.51.

21. Ivashkin VT, Drapkina OM, Mayev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;6:31-41 (In Russ.)

22. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2(6):335-48. DOI:10.1038/ncpendmet0190.

23. Drapkina OM, Chaparkina SO. The relationship of metabolic syndrome, aseptic inflammation and endothelial dysfunction. Rossijskie Medicinskie Vesti. 2007;12(3):67-75 (In Russ.)

24. Brouwers MCGJ, Simons N, Stehouwer CDA, et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia. 2020;63(2):253-60. DOI:10.1007/s00125-019-05024-3.

25. Tana C, Ballestri S, Ricci F, et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16(17):3104. DOI:10.3390/ijerph16173104.

26. Vovk EI. Non-alcoholic fatty liver disease as pro-atherogenic disease: diagnosis and treatment in general practice. Russian Medical Journal. 2017;1(2):68-79 (In Russ.)

27. Alexander M, Loomis AK, van der Lei J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367:l5367. DOI:10.1136/bmj.l5367.

28. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372-84. DOI:10.1016/j.jhep.2010.04.008.

29. Drapkina OM. RAAS and fibrosis. Hepatocardial connections. Russian Medical Journal. 2011;19(18):1136-9 (In Russ.)

30. Vesnina LJe. Lipid rafts: their role in the regulation of the functional state of cell membranes. Aktual'nye Problemy Sovremennoj Mediciny. 2013;1(2):5-10 (In Russ.)

31. Ismaiel A, Dumitrascu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review. Front Med (Lausanne). 2019;6:202. DOI:10.3389/fmed.2019.00202.

32. Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring). 2014;22:332-6. DOI:10.1002/oby.20624.

33. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. DOI:10.1016/j.jhep.2014.12.012.

34. Targher G, Day CP, Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2010;363:1341-50. DOI:10.1056/NEJMra0912063.

35. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258-67. DOI:10.1016/j.atherosclerosis.2013.07.052.

36. Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014;24(6):663-9. DOI:10.1016/j.numecd.2014.01.005.

37. Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology: WJG. 2014;20(7):1724-45. DOI:10.3748/wjg.v20.i7.1724.

38. Targher G, Valbusa F, Bonapace S, et al. Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes. PLoS ONE. 2013;8(2):e57183. DOI:10.1371/journal.pone.0057183.

39. Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012;35(2):389-95. DOI:10.2337/dc11-1820.

40. Myazin RG. Nafld and cardiovascular risks: clinic, diagnostic, features of therapy. Meditsinsky Sovet. 2019;12:82-6 (In Russ.) DOI:10.21518/2079-701X-2019-12-82-86.

41. Azimova MO, Blinova NV, Zhernakova YuV, Chazova IE. Obesity as s predictor for cardiovascular disease development: role of localized fat depot. Systemic Hypertension. 2018;15(3):39-43 (In Russ.) DOI:10.26442/2075-082X_2018.3/39-43.

42. World health statistics 2018: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization; 2018 [cited 2020 Jan 16]. Availlable from:

43. Livzan MA, Kolbina MV, Matoshina IV, et al. Hormones adipose tissue and non-alcoholic fatty liver disease at metabolic syndrome. Diary of Kazan Medical School. 2014;1(4):44-8 (In Russ.)

44. Liu KM, Khlynova OV. NAFLD as a model of a patient with high cardiovascular risk. Mezhdunarodniy Nauchno-issledovatel’skiy Zhurnal. 2017;5(59):147-51 (In Russ.) DOI:10.23670/IRJ.2017.59.023.

45. Fracanzani AL, Pisano G, Consonni D, et al. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE. 2016;11(9):e0162473. DOI:10.1371/journal.pone.0162473.

46. Mishina EE, Mayorov AY, Bogomolov PO, et al. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes Mellitus. 2017;20(5):335-42 (In Russ.) DOI:10.14341/DM9372.

47. Akhmedov VA. Interrelation of cardiac-vascular complications and non-alcoholic fatty liver disease. Russian Medical Journal. 2018;1(II):86-8 (In Russ.)

48. El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2019;20(9):2215. DOI:10.3390/ijms20092215.

49. Verbovoi AF, Tsanava IA, Verbovaya NI, Galkin RA. Resistin is a marker of cardiovascular diseases. Obesity and Metabolism. 2017;14(4):5-9 (In Russ.) DOI:10.14341/OMET201745-9.

50. Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Medical Council. 2015;13:58-63 (In Russ.) DOI:10.21518/2079-701X2015-13-58-63.

51. Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: An Adipokine with Cardiovascular Impact. Mediators Inflamm. 2013;2013:1-15. DOI:10.1155/2013/946427.

52. Livzan MA, Lapteva IV, Miller TS. Role leptin and leptinresistance to organization non-alcoholic fatty liver disease in persons with obesity and overweight. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2014;108 (8):27-33 (In Russ.)

53. Fedorova TA, Ivanova EA, Semenenko NA, et al. Clinical and laboratory aspects of chronic heart failure in patients with metabolic syndrome. Effektivnaya Farmakoterapiya. 2019;15(20):12-9 (In Russ.) DOI:10.33978/2307-3586-2019-15-20-10-16.

54. Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;170(10):57-65 (In Russ.) DOI:10.31146/1682-8658-ecg-170-10-57-65.

55. Gencer B, Auer R, de Rekeneire N, et al. Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. Atherosclerosis. 2016;245:181-6. DOI:10.1016/j.atherosclerosis.2015.12.004.

56. Gruzdeva OV, Borodkina DA, Belik EV, et al. Ghrelin Physiology and Pathophysiology: Focus on the Cardiovascular System. Kardiologiya. 2019;59(3):60-7 (In Russ.) DOI:10.18087/cardio.2019.3.10220.

57. Uchasova EG, Gruzdeva OV, Dyleva YuA, et al. The role of immune cells in the development of adipose tissue dysfunction in cardiovascular diseases. Russian Journal of Cardiology. 2019;24(4):92-8 (In Russ.) DOI:10.15829/1560-4071-2019-4-92-98.

58. Livzan M, Akhmedov V, Krolevets T, et al. The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease. Ter Arkhiv. 2016;88(12):62-8 (In Russ.) DOI:10.17116/terarkh2016881262-68.

59. Persico M, Masarone M, Damato A, et al. Non alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterol. 2017;17(1):35-44. DOI:10.1186/s12876-017-0592-y.

60. Khukhlina OS, Antoniv AA, Mandryk OY, et al. The role of endothelial dysfunction in the progression mechanisms of non-alcoholic steatohepatitis in patients with obesity and chronic kidney disease. Wiad Lek. 2019;72(4):523-6. DOI:10.36740/WLek201904103.

61. Pasarın M, La Mura V, Gracia-Sancho J, et al. Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD. PLoS ONE. 2012;7(4):e32785. DOI:10.1371/journal.pone.0032785.

62. Mehtiev SN, Mehtieva OA. Fat hepatic disease as a factor of risk change in cardiovascular «disasters» in patients with arterial hypertension. Lechashiy Vrach. 2015;5:66-71 (In Russ.)

63. Kade AH, Zanin SA, Gubareva EA, et al. Physiological functions of the vascular endothelium. Fundamental’nye Issledovaniya. 2011;11(3):611-7 (In Russ.)

64. Tsyrkunov VM, Andreev VP, Kravchuk RI, Kаndratovich IA. Clinical cytology of the liver: ito stellate cells (hepatic stellate cells). Journal of the Grodno State Medical University. 2016;(4):90-9 (In Russ.)

65. Gaus OV, Akhmedov VA. The impact of metabolic syndrome on the structural and functional state of the liver parenchyma. Experimental and Clinical Gastroenterology. 2016;(7):32-7 (In Russ.)

66. Livzan MA, Lapteva IV, Krolevets TS. Assessment of matrix metalloproteinases and their tissue inhibitors for non-invasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease. Eksperimental’naya i Klinicheskaya Gastroenterologiya 2016;131(7):25-31 (In Russ.)

67. Oganov RG, Denisov IN, Simanenkov VI, et al. Сomorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5-56 (In Russ.) DOI:10.15829/1728-8800-2017-6-5-56.

68. Zvenigorodskaya LA, Samsonova NG, Melnikova NV, Cherkasova EA. Hypolipidemic therapy in patients with non-alcoholic fatty liver disease. Experimental’naya i Klinicheskaya Gastroenerologiya. 2010;7:25-33 (In Russ.)

69. Dicheva DT, Kuznetsova EI. Modern aspects of nonalcoholic fatty liver disease patients treatment. Consilium Medicum. 2018;20(8):20-3 (In Russ.) DOI:10.26442/2075-1753_2018.8.20-23.

70. Drapkina O.M. Statin safety revisited data. Rational Pharmacotherapy in Cardiology. 2013;9(2):143-8 (In Russ.) DOI:10.20996/1819-6446-2013-9-2-143-14884.

71. Pose E, Trebicka J, Mookerjee RP, et al. Statins: Old drugs as new therapy for liver diseases? J Hepatol. 2019;70(1):194-202. DOI:10.1016/j.jhep.2018.07.019.

72. Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47(1):4-11. DOI:10.1016/j.dld.2014.07.170.

73. Korneeva ON, Drapkina OM. How to avoid statin hepatotoxicity in patients with obesity and liver disease? Focus on the combination of ursodeoxycholic acid and atorvastatin. Cardiovascular Therapy and Prevention. 2012;11(6):81-4 (In Russ.) DOI:10.15829/1728-8800-2012-6-81-84.

74. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122 (In Russ.) DOI:10.15829/1560-4071-2018-6-7-122.

75. Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol. 2013;5(9):470-8. DOI:10.4254/wjh.v5.i9.470.

76. Ionova ZI, Sergeeva EG, Berkovich OA, et al. Role of peroxisome proliferator-activated receptor α and ϒ-2 in primary and secondary prophylaxis of atherosclerosis. The Scientific Notes of the Pavlov University. 2016;23(2):15-20 (In Russ.)

77. Leonova MV. Clinical pharmacology of angiotensin II receptor blockers: valsartan. Meditsinskiy Sovet. 2014;(17):66-71 (In Russ.) DOI:10.21518/2079-701X-2014-17-66-71.

78. Yarek-Martynowa IR, Shamkhalova MSh. Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus. Sacharniy Diabet. 2010;(2):58-61 (In Russ.)

79. Kuzmina-Krutetskaya SR, Zakharova NV. Angiotensin II receptor blockers effectiveness in congestive heart failure. Diagnostika, Lechenie, Profilaktika Neinfekcionnyh Bolezney Cheloveka. 2011;3(40):159-66 (In Russ.)

80. Medvedev IN, Kuimova TA. The role and place of angiotensin II receptor blockers in the treatment of arterial hypertension in the metabolic syndrome. Russian Journal of Cardiology. 2007;5(67):97-9 (In Russ.)

81. Shaydyuk OYu, Taratukhin EO. Pleiotropic effect of nebivolol: recent data. Russian Journal of Cardiology. 2015;9(125):92-5 (In Russ.) DOI:10.15829/1560-4071-2015-09-92-95.

82. Nelson JE, Roth CL, Wilson LA, et al. Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: Possible role for MAPK and NF-κB? Am J Gastroenterol. 2016;111(6):852-63. DOI:10.1038/ajg.2016.51.


For citation:

Nelidova A.V., Livzan M.A., Nikolaev N.A., Krolevets T.S. Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy. Rational Pharmacotherapy in Cardiology. 2021;17(6):880-888. (In Russ.)

Views: 61

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)